Search Results - tumor

16 Results

Sort By:

Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)

Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Paul Robbins, Rami Yoseph, James Yang, Kenichi Hanada, Frank Lowery, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy

Abstract: Immunotherapy is a promising method of treating cancer that leverages the immune system to promote tumor rejection. However, certain somatic mutations in cancer cells confer resistance to T cell-mediated cytolysis. To improve the effectiveness of immunotherapies for cancer, there exists a need to prospectively identify patients who are most...

Published: 9/13/2024 | Inventor(s): Shashankkumar Patel, Nicholas Restifo

Keywords(s): CRISPR, diagnostic, Gene, Immunotherapy, T-cell, tumor

Category(s): Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Calcium (Ca2+) Flux-Dependent Method to Detect and Isolate Tumor Reactive T Cell Receptors (TCRs)

Abstract: T cells with T cell receptors (TCRs) for cancer-specific antigens are used for adoptive cell therapy (ACT), wherein a patient’s T cells are redirected against their own cancer. However, these isolated T cells may require further ex vivo manipulation to enhance their anti-tumor activity. The ex vivo manipulation of these T cells, or the selection...

Published: 4/8/2024 | Inventor(s): Douglas Palmer, Anna Pasetto, Nicholas Restifo, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, CA2+, Calcium Ion, Immunotherapy, Rosenberg, T Cell Receptor, TCR, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences

Abstract: Tumors can develop unique genetic mutations which are specific to an individual patient. Some of these mutations are immunogenic; giving rise to autologous T cells which are tumor-reactive. Once isolated and sequenced, these neoantigen-specific TCRs can form the basis of effective adoptive cell therapy cancer treatment regimens; however, current...

Published: 4/8/2024 | Inventor(s): Yong-Chen Lu, Zhili Zheng, Peter Fitzgerald, Steven Rosenberg

Keywords(s): CANCER, Immunotherapy, Single Cell, T-cell Receptors, TCR, tumor

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line

Worldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of...

Published: 7/25/2024 | Inventor(s): Vandana Sekhar, Patrizia Farci

Keywords(s): 2, Associated, CALCIUM, Cells, Huh7.5, Signal, TACSTD2-overexpressing, TRANSDUCER, tumor

Category(s): Collaboration Sought > Licensing

RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J

Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 341): https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=152.

Published: 7/25/2024 | Inventor(s): Bishop Hague

Keywords(s): Ateles-induced, B/J., Cell, DERIVED, HERPESVIRUS, Inbred, Line, Listed LPM Ano as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rabbit, RL-5-, RM, T, tumor, VLXXXX, WIXXXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Infectious Disease, Application > Research Materials

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Shihui Liu

Keywords(s): Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration

Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine Development

This invention relates to a genetically modified hemorrhagic fever virus that can be used as an effective live vaccine agent. Hemorrhagic fever evades the human immune response using the viral ovarian tumor domain (vOTU) protease, which inhibits critical host-immunity functions. The present genetically modified virus has a vOTU protease with decreased...

Published: 7/25/2024 | Inventor(s): Scott Pegan, MIchelle Deaton, Stuart Nichol, Eric Bergeron

Keywords(s): ABLATION, Activities, Crimean-Congo, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DeiSGylating, Deubiqutinating, Domain, DXXXXX, FEVER, HEMORRHAGIC, OVARIAN, Protease's, SIMULTANEOUS, tumor, Vaccine, virus

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Research Materials

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Published: 7/25/2024 | Inventor(s): Christopher Bachran, Stephen Leppla

Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...

Published: 7/25/2024 | Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas

Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials

1 2